Bavarian Nordic: Covid-19 vaccine beats Pfizer's on several parameters

New studies will further explore tentative yet promising data on Bavarian Nordic and Adaptvac's Covid-19 vaccine candidates at a larger scale. According to Bavarian Nordic VP Investor Relations & Communications, the company still hopes to receive economic aid from Danish authorities.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Moods are bright at Bavarian Nordic after data from the first human trials of the company's Covid-19 vaccine candidate, ABNCoV2, confirm that Bavarian is holding a well-tolerated inoculation, showing higher antibody levels than approved vaccines from firms like Pfizer and partner Biontech, says Bavarian Nordic Vice President of Investor Relations & Communications Rolf Sass Sørensen.

Antibody levels, which serve as an indicator for the degree of protection rendered by a vaccine, are measured relative to antibodies in a person having recovered from a Covid-19 infection.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs